Bristol-Myers Squibb's late stage hepatitis C product has been designated a Breakthrough Therapy Designation by the FDA. The company's investigational DCV Dual Regimen (daclatasvir and asunaprevir ...
Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...